Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, London, ON, Canada.
Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
Microbiome. 2023 Nov 25;11(1):263. doi: 10.1186/s40168-023-01703-x.
Inquiry of microbiota involvement in kidney stone disease (KSD) has largely focussed on potential oxalate handling abilities by gut bacteria and the increased association with antibiotic exposure. By systematically comparing the gut, urinary, and oral microbiota of 83 stone formers (SF) and 30 healthy controls (HC), we provide a unified assessment of the bacterial contribution to KSD.
Amplicon and shotgun metagenomic sequencing approaches were consistent in identifying multi-site microbiota disturbances in SF relative to HC. Biomarker taxa, reduced taxonomic and functional diversity, functional replacement of core bioenergetic pathways with virulence-associated gene markers, and community network collapse defined SF, but differences between cohorts did not extend to oxalate metabolism.
We conclude that multi-site microbiota alteration is a hallmark of SF, and KSD treatment should consider microbial functional restoration and the avoidance of aberrant modulators such as poor diet and antibiotics where applicable to prevent stone recurrence. Video Abstract.
对肠道微生物群在肾结石疾病(KSD)中的作用的研究主要集中在肠道细菌对草酸盐的潜在处理能力上,以及与抗生素暴露的增加之间的关联。通过系统比较 83 名结石形成者(SF)和 30 名健康对照者(HC)的肠道、尿液和口腔微生物群,我们对细菌对 KSD 的贡献进行了统一评估。
扩增子和 shotgun 宏基因组测序方法一致地确定了 SF 相对于 HC 的多部位微生物群紊乱。生物标志物分类群、减少的分类和功能多样性、核心生物能量途径的功能替换与与毒力相关的基因标志物、以及社区网络崩溃定义了 SF,但队列之间的差异并未扩展到草酸代谢。
我们得出的结论是,多部位微生物群改变是 SF 的标志,KSD 治疗应考虑微生物功能恢复,并避免不良饮食和抗生素等异常调节剂,在适用的情况下,以防止结石复发。视频摘要。